Skip to contentpdufa.bio

TransCon IL-2

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

TransCon IL-2 is an Ascendis Pharma A/S program. Its next catalyst is a Readout in Aug 2027.

ASND catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Ascendis Pharma A/S (ASND). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Aug 2027ASND

Specialist biotech funds holding ASND, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management10,281,496$2.34 billionfiled November 16, 2026
Avoro Capital Advisors5,050,000$1.15 billionfiled November 16, 2026
Perceptive Advisors971,521$221.3 millionfiled November 16, 2026
OrbiMed Advisors345,200$78.6 millionfiled November 16, 2026
Cormorant Asset Management15,000$3.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is TransCon IL-2's next FDA decision or readout?

The next tracked catalyst for TransCon IL-2 is a Readout in Aug 2027.

What happened at TransCon IL-2's most recent FDA decision?

No FDA decision for TransCon IL-2 is in our archive yet.

Who makes TransCon IL-2?

Ascendis Pharma A/S (ASND).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.